Amneal Pharmaceuticals Increases Estradiol Patch Production Amid Rising Demand
Amneal Pharmaceuticals is expanding its production capacity for estradiol patches to address significant demand following the removal of an FDA warning.
Stocks · News reference
Matthew Cascio Departs Amneal Pharmaceuticals for Laxxon Medical
Matthew Cascio, formerly Senior Director of Corporate Development and Head of Specialty Business Development at Amneal Pharmaceuticals, has been appointed as Vice President and Head of Business Development at Laxxon Medical.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amneal Pharmaceuticals Price Target Raised to $24.00
Amneal Pharmaceuticals received a price target increase to $24.00 per share, while maintaining an Overweight rating from analysts.
Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27
Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.